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Abstract: Invasive pulmonary aspergillosis (IPA) is an important cause of mortality in patients 
with hematologic malignancies. The reported incidence of IPA in the context of chronic obstruc-
tive pulmonary disease (COPD) seems to increase. Approximately 1%–2% of overall fatal cases 
of IPA occur in COPD patients. The combination of factors such as lung immune imbalance, 
long-term corticosteroid use, increasing rate of bacterial exacerbations over time, and malnutri-
tion are responsible for the emergence of IPA in these patients. The diagnosis of IPA is difficult 
to establish, which explains the delay in implementing accurate antifungal therapy and the high 
mortality rate. Persistent pneumonia nonresponsive to appropriate antibiotic treatment raises 
the concern of an invasive fungal infection. Definite diagnosis is obtained from tissue biopsy 
evidencing Aspergillus spp. on microscopic examination or in culture. Culture and microscopy 
of respiratory tract samples have a sensitivity and specificity of around 50%. Other diagnostic 
tools can be useful in documenting IPA: computed tomography (CT) scan, nonculture-based 
tests in serum and/or in bronchoalveolar lavage such as antibody/antigen tests for Aspergillus 
spp. More recent tools such as polymerase chain reaction or [1→3]-β-D-glucan have predictive 
values that need to be further investigated in COPD patients. Antifungal monotherapy using 
azole voriconazole is recommended as a first-line treatment of IPA. This review assesses the 
use of voriconazole in COPD patients.
Keywords: chronic obstructive pulmonary disease, corticosteroid, Aspergillus, invasive pulmonary 
aspergillosis, voriconazole
Introduction
Invasive pulmonary aspergillosis (IPA) is a life-threatening pneumonia characterized 
by lung parenchyma invasion with vasculature erosion and necrosis that is caused 
by opportunistic fungi belonging to the species Aspergillus. Aspergillus fumigatus 
is the most common species recovered from cases of IPA.1 The major risk factor 
for IPA development is host immunosuppression, especially related to long-term 
systemic phagocytic depletion. Consequently, IPA has been strongly associated 
with hematological cancer patients (including recipients of hematopoietic stem 
cell transplants) despite efforts over the past two decades to reduce its incidence, 
and improve diagnosis and treatment methods.2 Other subsets of high-risk patients 
include solid-organ transplant recipients, patients with advanced HIV infection, 
inherited immunodeficiency, those receiving other immunosupresors such as 
monoclonal antibodies, and critically-ill patients. Of particular concern are patients 
who may not be obviously immunocompromised but combine lung immune imbal-
ance with a systemic intrinsic and/or corticosteroid-induced immune dysfunction. International Journal of COPD 2009:4 280
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These patients do not strictly match with hematological 
cancer patient criteria regarding clinical presentation, 
radiological findings, and biological markers of infection. 
These include chronic obstructive pulmonary disease 
(COPD) patients that show the highest expansion in the 
number of reported cases over the past decade.3–8 COPD 
is a pulmonary disease characterized by airflow limita-
tion that is not fully reversible. The airflow limitation 
is usually progressive and associated with an abnormal 
inflammatory response of the lung to noxious particles 
or gases. The chronic airflow limitation characteristic 
of COPD is caused by a mixture of small airway disease 
(obstructive bronchiolitis) and parenchymal destruction 
(emphysema), the relative contributions of which vary 
from person to person. Four stages of COPD are defined 
from mild, moderate, severe, to very severe (stages I to IV, 
respectively).9 Airway colonization by Aspergillus spp. is 
a common feature in chronic lung diseases.10 Although 
cumulative factors that trigger lung invasiveness are not 
completely understood, the leading concern remains when 
and how appropriate antifungal treatment should be initi-
ated. This issue is critical considering the poor outcome 
unanimously reported in the literature of COPD patients 
suffering from IPA.5,6
Voriconazole is a synthetic antifungal agent belonging to 
the triazoles chemical family. Voriconazole has regulatory 
approval for primary treatment of IPA and has been recom-
mended for use as the initial therapy for patients with this 
disease.2,11 This review provides an overview of the use of 
voriconazole and the particular aspects that have to be taken 
in consideration in the setting of COPD. This includes the 
need to refer to pathophysiological processes underlying 
IPA and to diagnostic issues that we will discuss as decisive 
supports for antifungal treatment initiation.
Epidemiology
An accurate estimation of IPA incidence in COPD patients 
is difficult, partly due to the lack of infection surveillance 
measures. In a study including 595 patients with IPA, 9% 
suffered from nondetailed pulmonary diseases.12 In a review 
including 50 studies of aspergillosis case-fatality rate, COPD 
was the underlying condition in 26 out of 1941 patients 
(1.3%) with aspergillosis.13 Several autopsy studies from 
intensive care unit (ICU) patients confirm that invasive 
fungal diseases (IFD) are among the most commonly missed 
diagnoses.14,15 Taken together, these studies suggest that IPA 
incidence amongst COPD patients may be underestimated. 
Higher risk of IPA occurrence may be correlated with 
advanced stages of COPD. As reported in a recent series 
of 57 probable IPA, 36 patients (63.2%) were stage III 
and 21 (33.8%) were stage IV.16 The global mortality rate 
of IPA in COPD patients reported in the literature is high, 
ranging from 72% to 95%.5,6,16 This makes a sharp contrast 
with the latest outcome data from hematopoietic stem cell 
transplant recipients, where a clear trend toward a drop in 
attributable mortality has been observed in recent years 
(from 60%–70% to 40%).17
Pathophysiology
Aspergillus spp. are airborne fungi that undergo a biphasic-
growth process. Spores or conidia, which represent the form 
of environmental persistence and dissemination, are inhaled 
during breathing and their small size (2–3 µm) allows them to 
reach the lung alveoli. Conidia germinate to produce branch-
ing and septate filaments known as hyphae (∼2 to 10 µm in 
diameter), which are the invasive form responsible for tissue 
damage. Upper respiratory tract clearance of inhaled conidia 
is facilitated by tracheobronchial ciliary activity. Conidia are 
ingested and destroyed by airway macrophages that prevent 
germination to hyphal form. Germinating spores and hyphae are 
attacked by polymorphonuclear neutrophils (PMNs) through 
the release of oxidants and degranulation. Pulmonary dendritic 
cells ingest both conidia and hyphae, migrate to draining lymph 
nodes and instruct the T helper-cell response.18
The development of IPA in COPD patients is due to 
combined factors. First, nutritional depletion is prevalent in 
advanced COPD and clinical research has provided evidence 
that undernutrition in advanced COPD is associated with 
an increased mortality, notably related to lung infections.19 
A second factor is the impairment of ciliary function by 
chronic tobacco smoke and multiple episodes of infection 
reduce microbial pathogens clearance from lung airways.9 
Third, the use of broad-spectrum antibiotics in case of exac-
erbations affects the distribution of normal flora, which may 
lead to a shift toward development of fungal populations in 
airways. Furthermore, a recent study showed that A. fumigatus 
has the ability to grow as a biofilm in vivo which may enable 
chronic persistence within lungs and promote antimicrobial 
resistance.20 This is of significant concern for COPD patients 
in ICU with synthetic devices in lung airways (eg, endotra-
cheal tube). Finally, corticosteroids have significant impact 
on the distribution and function of neutrophils, monocytes, 
and lymphocytes.21,22 They also directly stimulate the growth 
of A. fumigatus in vitro possibly via the sterol binding 
protein in the fungus.23 Thus, intravenous (IV) corticosteroids 
treatment in COPD patients appears to be associated with a International Journal of COPD 2009:4 281
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rising incidence of IPA. Some reports also describe that high 
doses of inhaled corticosteroids may promote the occurrence 
of IPA.24–26
In summary, COPD is characterized by significant 
variability in local immune balance that impacts the patient 
ability to contain invasive fungal challenges over time. Taken 
together, the intrinsic progression of the disease characterized 
by an increasing rate of microbial colonization, the exacerba-
tions of viral and bacterial origins, the repetitive use of anti-
biotics, the necessity of occasional admissions in ICU with 
the requirement for invasive procedures, the steroid-induced 
immunomodulation, and the sepsis-related cycling fluctua-
tions of immune status from hyper- to anti-inflammatory 
phases (that can confine to immunoparalysis in extreme 
cases)27 create favorable conditions for the development of 
opportunistic invasive mould infections such as IPA.
Clinical features
The diagnosis of IPA in nonneutropenic patients is difficult 
because signs and symptoms are nonspecific such as fever, 
increased respiratory secretions, dyspnea exacerbation and 
high oxygen requirements, persistent bronchospasm despite 
elevated doses of corticosteroids. The occurrence of hemop-
tysis is less reported in COPD patients than in hematological 
patients. In the context of evolving COPD, persistent rapid-
developing infiltrative abnormalities on thoracic imaging 
and/or persistent pulmonary infection despite broad-spectrum 
antibiotics should trigger further investigations focused on 
fungal infection.
Assessing the diagnosis of IPA 
in COPD patients
Baseline criteria
The definitions have assigned three levels of probability for the 
diagnosis of IPA: proven, probable, and possible. Proven IPA 
can apply to any patient, regardless of whether the patient is 
immunocompromised, on the common basis that histopatho-
logical documentation of infection and/or a culture positive 
specimen from a normally sterile site is required. This usually 
involves use of invasive procedures to obtain tissue specimens 
which is rarely feasible, especially in COPD patients.
In 2007, an attempt to standardize definitions of IPA 
in COPD patients was proposed by Bulpa and colleagues 
that established a formal framework based on previously 
published information.5 The classification focused on 
advanced stages of COPD (stages III and IV). The collection 
of hyphae in a lung biopsy specimen remained the decisive 
argument for proven IPA. For probable and possible IPA, 
the recommendation was given to rely on a combination of 
criteria taking into account nonspecific changes on chest 
computed tomography (CT) imaging, positive cultures from 
lower respiratory tract and positive biological markers such 
as serum antibody and/or antigen tests.
Definitions of IFD in immunocompromised patients 
have been recently revised.28 Aside from proven IPA, the 
definition of probable and possible IPA in immunocompro-
mised patients is based on a combination of less-specific 
criteria within three categories: host factors, clinical mani-
festations (symptoms, signs, and radiological features), and 
mycological evidence. Probable IFD requires the presence of 
a host factor, a clinical criterion, and a mycological criterion. 
Cases that meet the criteria for a host and a clinical criterion 
but for which mycological evidence lacks are considered 
possible IFD. In this revised definition of IFD it has to 
be taken into account that predisposing host factors were 
extended to receipt of immunosuppressive agents includ-
ing prolonged use of corticosteroids, which is often the 
case in COPD patients. However, the revised definitions do 
not apply to critically ill patients in the ICU who, nonethe-
less, may include COPD patients that develop probable or 
possible IPA.
Diagnostic procedures
Lung biopsy
Establishing the presence of fungi in tissue gives the highest 
level of certainty in diagnosing IPA. Transthoracic percutane-
ous needle aspiration, video-assisted thoracoscopic biopsy, 
or transbronchial biopsies are standard procedures to obtain 
histopathological evidence of IPA that reveals characteristic 
angular dichotomously branching septate hyphae on direct 
microscopic examination and/or Aspergillus spp. on culture. 
A yield in the range of 50% has been reported for percuta-
neous biopsy needle, which indicates that a negative result 
should not rule out the diagnosis.29 However, the invasive-
ness of these procedures exposes COPD patients to severe 
respiratory and/or bleeding complications.
Microbiological examination
Sputum
Direct examination of sputum can be rapidly performed and 
is reported to be positive for Aspergillus in half of all IPA 
cases.30 The use of fluorescence techniques optimizes the 
yield of microscopic examination up to 80%–90%.31
Based on literature data, the significance of positive spu-
tum cultures for Aspergillus in COPD patients developing International Journal of COPD 2009:4 282
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pneumonia is not clearly established. From a practical point 
of view, the possibility of IPA has to be taken into consid-
eration in each case of advanced steroid-dependant COPD 
in patients experiencing antibiotic-resistant pneumonia. 
The recovery of several positive culture samples in a row in 
the course of such an ongoing pneumonia is clearly evocative 
of the diagnosis. In that case, further investigations must be 
triggered if possible and concern about antifungal treatment 
must be raised.
Fiberoptic flexible bronchoscopy
Fiberoptic flexible bronchoscopy with sampling of deep 
airway secretions and bronchoalveolar lavage (BAL) allows 
samples to be collected that can be processed for micro-
scopic examination, fungal culture, and antigen or molecular 
detections. It has to be taken into account that BAL might 
be difficult to obtain in patients with low respiratory status 
due to advanced COPD. The macroscopic visualization of 
ulcerative lesions and/or pseudomembranes is suggestive of 
Aspergillus-related infection. The yield of culture positive 
specimens has ranged from 46% to 77%.30,32–35 BAL is more 
often positive in cases of prolonged pneumonia or extensive 
pulmonary lesions.
In summary, the isolation of Aspergillus spp. from the 
respiratory tract of a COPD patient with pneumonia confronts 
to two possibilities: colonization or current invasive disease. 
BAL is the technique that may provide the wider range of 
information through direct visualization of bronchial tree, 
and collection of distal samples. But BAL is often difficult 
to perform. Therefore, the diagnosis is more likely to rely on 
positive culture of sputum and bronchoaspirates. The posi-
tive predictive value for IPA of repeatedly positive sputum 
or bronchoaspirate cultures for Aspergillus spp. in advanced 
COPD patients must not be underestimated in the context of 
antibiotic-resistant pneumonia.
Biological markers
Detection of antibodies
A positive serum antibody test for A. fumigatus remains one 
of the biological criteria proposed for the diagnosis of IPA 
in COPD according to Bulpa and colleagues.5 However, 
an increase in antibodies directed toward Aspergillus spp. 
requires a functional immune status and a pattern of infec-
tion long enough to generate a significant antibody response. 
Long-term steroid-dependant COPD patients are likely to 
develop weaker antibody responses and brief courses of 
IPA often do not allow seroconversion and the follow-up of 
kinetic antibody responses.
Antibody detection is more likely used in diagnosis of 
chronic pulmonary aspergillosis for which it is reported that 
high titers of antibodies are more common in more seriously 
ill patients, and generally would increase during exacerba-
tions.36 On this basis, the monitoring of titers to detect the 
passage of chronic semi-invasive disease to invasive disease 
might be useful.
Serological techniques
The development of nonculture-based diagnostics has focused 
on the detection of surrogate markers for Aspergillus spp., 
such as the galactomannan (GM) antigen, [1→3]-β-D-glucan 
and the detection of Aspergillus DNA by polymerase chain 
reaction (PCR).
GM is a major Aspergillus cell-wall component that 
is released during the hyphal growth phase. It is used as 
an exo-antigen for the purpose of Aspergillus detection.37 
The GM serum assay has been extensively investigated in 
immunocompromised patients. A meta-analysis including 
27 studies regarding the value of the GM serum assay 
for surveillance of IPA in hematological and solid-organ 
transplant recipient patients ultimately revealed a moderate 
accuracy for diagnosis of IPA with various median sensitivity 
and specificity: for proven cases alone, which were 71% and 
89% respectively; combining proven and probable cases, 
which were 61% and 93%, respectively.38 The test is more 
useful in patients who have hematological malignancy or 
who have undergone hematopoietic cell transplantation than 
in solid-organ transplant recipients. The use of GM assay for 
the diagnosis of IPA in patients with COPD might be very 
limited. A retrospective study which enrolled critically ill 
patients without malignancy, 27% of whom were COPD 
patients, is worth mentioning:39 the diagnostic value of the 
GM assay demonstrated a sensitivity of only 53% in patients 
with proven or probable IPA (cut-off value of 1 ng/mL). This 
indicates clearly that data from patients with malignancies 
and after solid organ transplantation cannot be extrapolated 
to other critical conditions. In the largest series available of 
IPA in COPD patients, 44% of the 34 patients tested were 
positive (cut-off value of 0.5 ng/mL).16 The low sensitivity 
of GM in serum of these patients with values in a range of 
40%–55% is a major limitation.
Because GM is a water-soluble carbohydrate, it can also 
be detected in BAL fluid. In small clinical studies among 
patients with hematological malignancies and solid organ 
transplant recipients, the sensitivity of the GM assay applied 
to BAL fluids ranges from 85% to 100% (cut-off value of 
1.5 ng/mL).40–43 A recent prospective study conducted in ICU International Journal of COPD 2009:4 283
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patients, of whom 8% were COPD patients, the sensitivity 
and specificity of GM detection in BAL fluid was 88% and 
87%, respectively (cut-off value of 0.5 ng/mL).44 Conse-
quently, there is an increasing tendency to use these samples 
for diagnosis of IPA despite the fact that the assay is not 
specifically validated for detection of GM in this fluid.
Several circumstances can be source of false-positives for 
the GM antigen test in either serum or BAL fluid. First, the 
false-positive reactivity can be caused by gastro-intestinal 
translocation of fungal GM from contaminated food 
or drink,45 or by the use of the intravenous antibiotics 
piperacillin–tazobactam and amoxicillin–clavulanic acid.46,47 
Second, an important factor that affects the release of GM 
antigens is antifungal drug therapy. Different animal and 
human studies have shown decreased sensitivity of the GM 
assay when using prophylactic antifungal drugs.48,49
The [1→3]-β-D-glucan is a cell wall component of 
many filamentous fungi and yeasts, including Aspergillus 
and Candida species. Reproducible assay results, with high 
specificity and a high positive predictive value, demonstrated 
that use of an assay to detect serum [1→3]-β-D-glucan 
derived from fungal cell walls might be a useful diagnostic 
adjunct for invasive fungal infection.50 A single case of positive 
[1→3]-β-D-glucan values during fatal IPA in a COPD patient 
has been reported which indicated a value increase at day 
15 over the course of a 21 days-illness.51 In addition, false-
positive tests have been found in patients after hemodialysis, 
cardiopulmonary bypass surgery, high-dose immunoglobulin 
treatment, after exposure to glucan-containing gauze, and in 
cases of bacterial infections among ICU patients.52,53 Hence, 
the usefulness of [1→3]-β-D-glucan in the diagnosis of IPA 
has clearly to be further evaluated.
Amplification of nucleic acid by PCR technology for the 
diagnosis of IPA is being increasingly studied. Yet, it is not 
included in the definitions of IPA due to the lack of standard-
ization. It can be applied to serum and BAL specimens.54–59 
Experience is still limited and a recent meta-analysis yielded 
a sensitivity and specificity for two consecutive positive 
samples of 75% and 85%, respectively.60 However, most of 
studies were done in the hematological setting. Therefore, 
the role of PCR in patients with COPD is mostly unknown. 
As for the GM assay, there are factors that potentially have 
an impact upon the clinical sensitivity of PCR: the magnitude 
of the quantitative PCR signal decreases with antifungal 
therapy, potentially causing false-negative PCR results.61 The 
colonization of the respiratory tract by Aspergillus spp. may 
suggest a low positive predictive value.56 Finally, patients 
at risk for IPA are often prescribed a multitude of drugs 
and fluids, all of which may act as nonspecific inhibitors of 
the PCR. For example, anticoagulants inhibit PCR, thereby 
limiting its sensitivity.62
In summary, the use of GM, [1→3]-β-D-glucan tests, 
and Aspergillus PCR as serological and molecular markers 
cannot be wisely advocated for routine use in COPD patients, 
and caution is warranted in the interpretation of positive test 
results in patients without a clinical suspicion of pulmonary 
infection and negative test results in patients with persisting 
pneumonia. The finding of sequentially positive GM tests 
in serum or BAL fluid together with a positive Aspergillus 
PCR, in a patient with persisting pulmonary infection who 
carries one or more risk factors, is highly indicative for IPA 
and would justify considering antifungal therapy.
radiology
Chest CT is an important tool for the diagnosis of IPA in 
neutropenic patients. CT has been proven effective in the 
absence of evident lesions on a conventional chest X-ray. 
Radiological findings might include nodules with rapid 
growth and/or cavitations. A “halo sign” (corresponding to 
a pulmonary mass surrounded by a zone of lower attenua-
tion with ground-glass opacification produced by adjacent 
hemorrhage) and/or the “air crescent sign” (corresponding to 
crescentic radiolucencies around a nodular area of consolida-
tion) may be present.63–71
However, thoracic imaging in mechanically ventilated 
ICU patients is less helpful due to many confounding factors 
such as atelectasis and, sometimes major, pleural effusions. 
A lower sensitivity (from 5% to 24%) of the halo sign 
and air crescent sign in non-neutropenic patients has been 
reported in the literature.39,72,73 In the study by Guinea and 
colleagues, the worsening of imaging data is one of the five 
independent variables suggestive of IPA in patients with 
COPD and clinical isolation of Aspergillus spp. from lower 
respiratory samples.16
Antifungal therapy
In 2002, a large randomized trial reported an improved 
response and survival rate for patients with IPA who received 
therapy with voriconazole compared with patients who 
received standard deoxycholate amphotericin B therapy 
(so far, liposomal formulations of amphotericin B and vori-
conazole have not been compared in clinical trials for the 
treatment of IPA). This led to the recommendation to use 
voriconazole as the primary treatment of IPA.74 However, 
this study included 277 patients but only 16 were receiving 
corticosteroids as predisposing conditions; the majority of International Journal of COPD 2009:4 284
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the remaining patients had hematological malignancies. 
Therefore, the evidence of the superiority of voriconazole 
over amphotericin B for the treatment of IPA in patients 
with COPD cannot be inferred from this study. Further-
more, rather conflicting data are available in experimental 
models. In a model of lethal infection in guinea pigs, two 
studies concluded that voriconazole therapy at 10 mg/kg/day 
prolonged survival compared to that of guinea pigs treated 
with conventional amphotericin B at 1 and 1.25 mg/kg/day, 
respectively.75,76 Another recent study concluded that the 
efficacy of high dose liposomal amphotericin B (at 5 and 
10 mg/kg) was superior to that of voriconazole (10 mg/kg) 
in a mouse model of pulmonary aspergillosis.77 Obviously, 
there is an urgent need for adequately-designed prospective 
clinical trials comparing voriconazole to conventional and/or 
liposomal formulation of amphotericin B in nonimmunocom-
promised high-risk patients, COPD inclusively.
Voriconazole is a synthetic triazole compound that exerts 
an inhibitory effect on two kinds of Aspergillus cytochrome 
P450-dependant enzymes: the first enzyme targeted is 
lanosterol 14-α-demethylase that participates in ergosterol 
biosynthesis. Inhibition of this enzyme results in altered cell 
membrane function. The second group of targeted enzymes 
belongs to the fungal respiration chain. Their inhibition limits 
cell growth and replication and ultimately leads to cell death. 
Triazoles are generally considered as fungistatic.
Voriconazole is formulated as tablets or as sulfobutyl-ether 
cyclodextrin (SEC) solution for IV administration. SEC and 
voriconazole dissociate in plasma. As SEC is renally cleared 
and consequences of its plasma accumulation are still uncertain, 
caution is advised when using the IV formulation in patients with 
renal impairment (creatinine clearance 50 mL/min).2,78 This 
concern does not apply to orally administrated voriconazole.
The oral formulation has 90% to 96% bioavailability. The 
absorption is better when administered either one hour before 
or after a meal. No formal relationship has been established 
between body weight and kinetics justifying the fixed dose 
in adult patient 40 kg. Voriconazole is mostly hepatically 
metabolized, with only 5% of the drug appearing unchanged 
in the urine. The elimination half-life of ∼6 hours warrants 
twice-daily dosing. Voriconazole is biotransformed by cyto-
chrome P450-dependant isoenzymes CYP2C19, CYP2C9, and 
CYP3A4 acting as both a substrate and an inhibitor of these 
isoenzymes. This extensive and saturable hepatic metabolism 
explains the nonlinear pharmacokinetic profile of voriconazole 
in adults, with maximum concentration in plasma and area 
under the curve increasing disproportionally with increasing 
dose. Once voriconazole concentrations start approaching or 
exceeding the saturation level of the enzyme, small increases 
in the voriconazole dose will result in much larger increases in 
the drug concentration.79,80 Thus, intra- and interpatient voricon-
azole concentrations in serum may vary considerably depending 
on age, drug dose, concurrent illness, underlying liver function, 
drug-to-drug interactions, or genetic polymorphisms affecting 
cytochrome CYP2C19-mediated metabolism.78,81 Single-
nucleotide polymorphisms contributing to slow metabolism 
are represented in ∼3% of white Europeans and in higher fre-
quencies, from 15% to 20%, among non-Indian Asian popula-
tions.82 An analysis that attempted to determine the relationship 
between voriconazole plasma concentrations and abnormal 
liver function test values, indicated that the risk of developing 
elevated liver function test values increased by 7% to 17% for 
every 1 µg/mL increase in the random voriconazole concentra-
tion.83 As no threshold was found, the investigators argued that 
therapeutic drug monitoring of voriconazole concentrations 
is not more helpful in predicting abnormal liver function test 
values than measuring liver function directly. Another recent 
study emphasizes that therapeutic drug monitoring of voricon-
azole improves the efficacy and safety of therapy in severely 
ill patients with invasive mycoses. Among the 52 enrolled 
patients, a large variability in voriconazole trough blood levels 
was observed, ranging from 1 mg/L (the minimum inhibi-
tory concentration at which, for most fungal pathogens, 90% 
of isolates are susceptible) to 5.5 mg/L (the potentially toxic 
threshold).84 Lack of response to therapy was more frequent in 
patients with low voriconazole levels  1 mg/L (six patients, 
five of whom had IPA) than in those with voriconazole levels 
above that limit. In these patients, blood levels 1 mg/L were 
reached after increasing the voriconazole dosage, with resolu-
tion of infection meaning that patients subsequently responded 
to therapy after their voriconazole daily dose was increased 
without the addition of a second antifungal to the treatment 
regimen. This result suggests that, although pharmacokinetic 
variability is a factor possibly contributing to the poor clini-
cal outcome, dosage of voriconazole allows the correction of 
suboptimal serum levels. Among 16 patients with voriconazole 
trough blood levels  5.5 mg/L, five patients presented with 
neurological toxicity. In all cases, discontinuation of therapy 
resulted in prompt and complete neurological recovery. Thus, 
detection of voriconazole trough levels outside the therapeutic 
interval of 1–5.5 mg/L during the first week of therapy may 
help prevent treatment failures and anticipate the occurrence 
of drug-related toxicity.
Voriconazole diffuses widely in tissues with an emphasis 
on CSF levels which can reach up to 50% of plasma levels. 
Pharmacokinetics of voriconazole has been studied in International Journal of COPD 2009:4 285
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conditions that might be relevant with COPD status:85 delivery 
of voriconazole by a jejunostomy twice daily appears feasible 
whether tablets are crushed or not. Consistently, nasogastric 
administration through nasogastric tube can be an alternative 
option to IV injection for mechanically ventilated patients 
although cautious has to be raised on intact intestinal absorp-
tion in this category of patients. Consequently, patient medi-
cations should be reviewed for drug interactions. Briefly, the 
main drugs that potentially increase voriconazole concentra-
tions are erythromycin, indinavir, ranitidine, cimetidine, and 
omeprazole. Drugs that potentially decrease voriconazole 
concentrations are principally rifampicin (probably rifabutin as 
well) and phenytoin. Kinetics of other co-administrated drugs 
such as cyclosporine, digoxin, and phenytoin may be notably 
altered by voriconazole which implies adapting the dosages of 
some of these drugs based on the determination of their blood 
concentrations.85
Voriconazole’s profile of adverse reactions include tran-
sient visual disturbances (principally photopsia), hepatotoxic-
ity (elevated serum bilirubin, alkalin phosphatase, and hepatic 
aminotransferase enzyme levels) which may be dose limiting, 
and skin rash usually in sunlight-exposed areas. Visual and 
auditory hallucinations have been reported, mainly occurring 
upon receipt of initial loading doses.86 Other side effects have 
been reported such as confusion, and pneumonitis.81,87
Treatment of IPA with voriconazole in adults is initiated 
with a loading dose of 6 mg/kg IV every 12 hours for two doses 
on the first day, followed by 4 mg/kg every 12 hours; ultimate 
oral dosage is 200 mg every 12 hours. Primary combination 
therapy is not routinely recommended based on the lack of 
clinical data. Addition of another agent or switch to another 
drug class for salvage therapy may be considered in individual 
patient cases. Duration of therapy for most conditions associ-
ated with IPA has not been optimally defined. Duration should 
be from admission to treat until resolution or stabilization of 
all clinical and radiologic manifestations. Reversal of immuno-
suppression, if feasible, is important for a favorable outcome. 
The question whether long-term steroid treatment should be 
maintained, decreased, or interrupted should be addressed.
Conclusion
There are still many questions that need to be addressed and 
understood in the diagnosis and treatment of IPA in COPD 
patients. The high mortality rate is partly related to the delays 
in diagnosis and treatment because of non-specific symptoms 
and difficulties to meet gold standard criteria. A persistent 
pulmonary infection despite broad-spectrum antibiotics associ-
ated with abnormal CT thoracic imaging should trigger further 
investigations focused on moulds. Tissue biopsy evidencing 
Aspergillus spp. on microscopic examination or in culture is the 
gold standard but is difficult to obtain. Culture and microscopy 
of respiratory tract samples obtained by fiberoptic flexible 
bronchoscopy with sampling of deep airway secretions and 
BAL have an overall sensitivity and specificity of around 50%. 
Combining noncultured-based diagnostic tools in serum and/or 
BAL (eg, PCR and GM or GM and [1→3]-β-D-glucan) is an 
important research direction that may improve the overall pre-
dictive value of these systems in patients. Antifungal therapy 
may be considered in COPD patients with rapidly progressive 
antibiotic-resistant pneumonia and should be started in that 
case when cultures for Aspergillus spp. or sequentially positive 
GM (in serum or BAL) are positive. The antifungal triazole 
voriconazole is recommended to be the first line treatment of 
IPA despite the lack of specific data in COPD patients. Based 
on the nonlinear metabolic elimination of this drug, a follow-up 
of voriconazole blood levels may be useful during the first 
week of therapy.
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